Use of Information
We grant you a limited, revocable, and non-exclusive license to access and make personal, non-commercial use of the Website. You have no rights in or to the Information, and you will not use, copy or display the Information, except as permitted under these Terms. No other use is permitted without our prior written consent. Unauthorized use of the Information may result in violation of copyright, trademark, and other laws.
Copyright & Trademarks
INOVIO, Powering DNA Medicines, and the INOVIO logo are trademarks of INOVIO. Use, reproduction, copying, or redistribution of these trademarks, without the written permission of INOVIO is prohibited. Other trademarks are owned or used under license by their respective owners.
The entire content of this INOVIO website, including any images or text, is protected by copyright. In consideration for your agreement to these terms and conditions, INOVIO grants you a personal, non-exclusive, non-transferable license to access and use this website. It is the policy of INOVIO to enforce its intellectual property rights to the fullest extent permitted under law. The use or misuse of these trademarks, copyrights, or other materials, except as permitted herein, is expressly prohibited and may be in violation of copyright law, trademark law, communications regulations and statutes, and other laws, statutes, and/or regulations.
This Website provides information on various health topics, and may become out of date over time. The Website is not intended to provide any medical advice and should not be considered such.
INOVIO’s Website may contain links to websites operated and maintained by other parties (external websites). INOVIO is not responsible for the content of any external websites, and links to these sites are not an endorsement of the content. INOVIO does not make any representation regarding the accuracy of content on external websites.
This Website contains certain forward-looking statements relating to our business, including our plans to develop DNA medicine candidates, including INO-4800, our expectations regarding our research and development programs, as well as commercialization activities, including the planned initiation and conduct of clinical trials, the availability and timing of data from those trials and our manufacturing and commercialization strategy and tactics. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and manufacturing and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2019 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
News & Press Releases
This INOVIO Website may contain information, news, and/or press releases, the content of which is accurate or current only as of the date of the particular information, news, press release, or posting. INOVIO does not update press releases once they have been made public.
© Copyright 2022 INOVIO Pharmaceuticals. All rights reserved.